Yasmin, Yaz Alleged Blood-Clotting Lawsuits Update: Resource4thePeople Reports Bayer Settles Nearly 5,000 Cases for $1 Billion and also now Settling Gall Bladder Cases
Bayer’s annual report details progress of consolidated federal court litigation involving claims that the use of the popular contraceptives allegedly caused life-threatening side effects. Resource4thePeople attorneys continue to offer free consultations to consumers inquiring about possible compensation for blood clot risks.
San Diego, CA (PRWEB) April 27, 2013
Resource4thePeople is updating consumers today with news about the progress of consolidated federal court lawsuits* claiming that the popular birth control pills Yaz and Yasmin allegedly can cause blood-clotting problems that plaintiffs claim may be life-threatening.
Germany pharmaceutical giant Bayer has detailed in its annual report** that it has settled about 4,800 of these lawsuits for over $1 billion and that there are over 13,000 claimants still seeking damages over side effects, reports Resource4thePeople.
“As of February 12, 2013, Bayer had reached agreements, without admission of liability, to settle the claims of approximately 4,800 claimants in the U.S. for a total amount of about US$1 billion,” according to the annual report.
Bayer also said that it, “is only settling claims in the U.S. for venous clot injuries (deep vein thrombosis or pulmonary embolism) after a case-specific analysis of medical records on a rolling basis. Such injuries are alleged by about 3,200 of the pending unsettled claimants. Bayer will continue to consider the option of settling individual lawsuits in the U.S. on a case-by-case basis.”
Resource4thePeople is also updating consumers with news that Bayer also has agreed to pay up to $24 million to settle other lawsuits involving allegations over gall bladder side effects.These settlements are a different part of this consolidated litigation in U.S. District Court for the Southern District of Illinois in which plaintiffs claimed that they suffered gall bladder injuries because they used Yaz and Yasmin as contraceptives.**
Reuters News Service reported*** that the settlements also include Yaz and Yasmin cases in state courts in California, New Jersey and Pennsylvania.
“Under the agreement, Bayer will pay $2,000 to plaintiffs who suffered gallbladder injuries and $3,000 to individuals who had their gallbladders removed, according to the agreement,” Reuters reported.
“The fact that there has been a significant increase in the number of Yaz and Yasmin blood-clotting lawsuits does not preclude other consumers who may have suffered such side effects from seeking compensation in their cases,” said Resource4thePeople.
“We have been receiving numerous inquiries about whether it is too late to file a Yaz or Yasmin blood-clotting lawsuit. The answer is no. However every case is different and consumers are urged to take advantage of the free consultations our national team of attorneys are offering to evaluate the legal options for any consumer.”
Women who have filed Yaz and Yasmin blood-clotting lawsuits have claimed that they suffered blood clots, deep vein thrombosis, strokes and pulmonary embolisms as a result of their use of the contraceptives according to allegations contained in their lawsuits.*
Reuters in its report said that since 2009, Bayer has been hit by a wave of lawsuits claiming that the company knew or should have known of the health risks of the contraceptives and failed to warn users.
Bayer is also facing class actions lawsuits over the drugs in Canada, according to the article.
The federal court system has consolidated the thousands of Yaz and Yasmin blood-clotting lawsuits filed over claims of severe health problems into a multidistrict litigation.
Court records show that this special litigation is now in pre-trial evidence gathering and settlement talks before a federal judge who is overseeing thousands of such lawsuits in Illinois.*
Resource4thePeople also is alerting consumers to details of an April 10, 2012 Food and Drug Administration warning**** about Yaz and Yasmin blood-clotting side effects:
“The U.S. Food and Drug Administration (FDA) has completed its review of recent observational (epidemiologic) studies regarding the risk of blood clots in women taking drospirenone-containing birth control pills. Drospirenone is a synthetic version of the female hormone, progesterone, also referred to as a progestin. Based on this review, FDA has concluded that drospirenone-containing birth control pills may be associated with a higher risk for blood clots than other progestin-containing pills. FDA is adding information about the studies to the labels of drospirenone-containing birth control pills.”
In its announcement the FDA said that “The revised drug labels (Beyaz, Safyral, Yasmin and Yaz) will report that some epidemiologic studies reported as high as a three-fold increase in the risk of blood clots for drospirenone-containing products when compared to products containing levonorgestrel or some other progestins, whereas other epidemiological studies found no additional risk of blood clots with drospirenone-containing products. The labels also will include a summary of the previously released results of an FDA-funded study of the blood clot risk.”
Resource4thePeople said that additional inquiries about Yasmin and Yaz claims are coming in over news about a controversial Canadian case.
As reported by the Canadian Broadcasting Company (CBC) the British Columbia coroner´s office refused an autopsy request by the family of a woman who died from blood clots after being prescribed Yasmin.*****
The family then spent $1,200 out of their own pockets and their pathologist found that Yasmin and the woman´s obesity put her at risk of suffering the fatal blood clots, according to the report.*****
“According to the CBC the victim´s family is now seeking legal advice to determine whether they will join in the litigation against the manufacturers of Yasmin,” said Resource4thePeople. “This case involves similar allegations to those made in thousands of Yaz and Yasmin lawsuits that have been filed in the United States.
- In re: Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation MDL No. 2100, U.S. District Court, Southern District of Illinois
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/4/prweb10673957.htm